The market size of the Global Antisense Oligonucleotide Therapeutics market in the year 2021 is valued at 21.91 billion and is predicted to reach 64.46 billion by the year 2030 at an 12.9% CAGR during the forecast period.
Curious about this latest version of report? Obtain Report Details @ https://www.insightaceanalytic.com/report/global-antisense-oligonucleotide-therapeutics-market/1245
Antisense oligonucleotides (ASOs) are 15–25, not oligonucleotides designed to tie complementary RNA targets for the degradation. They’re made so that they can change the synthesis of a certain protein and so prevent disease processes. ASOS provide intriguing therapy possibilities for a variety of medical conditions. Another factor supporting the worldwide market’s growth is a strong pipeline. Another method used by industry competitors to establish their position in the oligonucleotide therapeutics market is the application of new molecules. Precision medicine techniques are allowed by the new and innovative oligonucleotides, which may be created to selectively target any gene with minimum side effects. One of the primary reasons driving growth in the global antisense oligonucleotides market is the increasing number of launches of innovative Antisense Oligonucleotides products by leading market participants over the forecast period.
Furthermore, the presence of essential market players and increased collaboration among significant companies for market penetration in the area give opportunities for market growth in the future years. Furthermore, ‘ mergers and acquisitions to enhance their product offerings are expected to be a significant driver for the worldwide antisense oligonucleotides market. However, the regulatory organizations have set strict manufacturing requirements and high medication efficiency standards for approval of this medicine, extending the approval process and limiting the market growth over the upcoming years.
List of Prominent Players in the Antisense oligonucleotide therapeutics Market:
Antisense Therapeutics Limited
Atlantic Healthcare plc
Nippon Shinyaku Co.
Wave Life Sciences
Other Prominent Player
Research undertaking and funding in the synthesis of oligonucleotides are expected to add to the increasing demand. Chemically produced oligonucleotides have had their technology-enhanced, resulting in the development of more robust and increased half-life molecules. Furthermore, key players’ mergers and acquisitions to enhance their product offerings are expected to be a major driver for the worldwide antisense oligonucleotides market. Furthermore, the presence of important market players and increased collaboration among significant companies for market penetration in the area give opportunities for market growth in the future years.
The prime challenge is the lack of awareness in developing countries, which is predicted to reduce the growth of the antisense oligonucleotide therapeutics market. However, the high cost of antisense oligonucleotide therapeutics and the availability of synthetic chemicals are factors expected to hamper the overall growth of the antisense oligonucleotide therapeutics market over the coming years. Furthermore, developing a new set of unique regulatory requirements is a difficulty that is inhibiting the worldwide antisense oligonucleotide market’s growth. The number of patients has been growing due to the COVID-19 epidemic, resulting in a worldwide or partial shutdown to preserve social distance.
According to a recent report, prominent companies in the worldwide antisense oligonucleotide therapies industry are incurring unprecedented economic losses owing to interruptions in global supply chains.
The North America antisense oligonucleotide therapeutics market is projected to record a major market share in terms of revenue and is projected to grow at a high CAGR. This is due to the region’s rising approval of innovative antisense oligonucleotide medicines. Furthermore, a strong pipeline is expected to contribute significantly to the growth of the antisense oligonucleotides market in North America. To improve their product offers in antisense oligonucleotides, key firms in Europe are focusing on strategic mergers and acquisitions. This is also predicted to help the antisense oligonucleotides industry in Europe expand. Moreover, the presence of key market players and increasing collaboration among major players for market penetration in the region provides the opportunity for the growth of the global antisense oligonucleotide therapeutics market.
- In Jan 2022, Biogen Inc. and Ionis Pharmaceuticals, Inc. jointly announced that Biogen had exercised its option to purchase from Ionis a global, exclusive, royalty-bearing license to manufacture and commercialize BIIB115/ION306. The businesses have formed a broad strategic alliance to discover breakthrough therapeutics for neurological illnesses.
Antisense Oligonucleotide Therapeutics Market Segmentation:
Antisense Oligonucleotide Therapeutics Market Segmentation: By Therapy Estimates & Trend Analysis
Antisense Oligonucleotide Therapeutics Market Segmentation: By Molecule Target Indication Estimates & Trend Analysis
- DNA Molecule
- RNA Molecule
Antisense Oligonucleotide Therapeutics Market Segmentation: By Target Indication Estimates & Trend Analysis
- Duchenne Muscular Atrophy
- Spinal Muscular Atrophy
- Familial Chylomicronemia Syndrome
- Amyotrophic Lateral Sclerosis
- Familial Partial Lipodystrophy
- Hereditary Transthyretin-Mediated (hatter) Amyloidosis
- Huntington’s Disease
Request for ToC/Proposal: https://www.insightaceanalytic.com/request-sample/1245